

[Rifapentine](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines](#)

Codes ATC: [J04AB05](#)

EMLc

Indication

Latent tuberculosis Code ICD11: [1B14](#)

INN

Rifapentine

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Oral > Solid > dispersible tablet: 150 mg (EMLc)

Oral > Solid > tablet: 150 mg ; 300 mg

Historique des statuts LME

Ajouté pour la première fois en 2015 ([TRS 994](#))

Modifié en 2021 ([TRS 1035](#))

Modifié en 2025 ([TRS 1064](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Rifapentine](#)

DrugBank

[Rifapentine](#)

Résumé des preuves et recommandation du comité d'experts



The Expert Committee recognized that age-appropriate, child-friendly formulations of medicines for the treatment of tuberculosis, when available and quality-assured, are essential public health interventions to meet the needs of paediatric patients. The Committee noted that currently listed rifapentine formulations for tuberculosis preventive treatment on the EMLc are 150 mg and 300 mg conventional tablets, which may not be acceptable for paediatric patients unable to swallow solid dosage forms. The 150 mg dispersible tablet rifapentine formulation is prequalified by WHO and is available through the Stop TB Partnership global drug facility. Based on these considerations, the Expert Committee recommended the addition of rifapentine 150 mg dispersible tablets to the core list of the EMLc for tuberculosis preventive treatment in accordance with recommendations in WHO guidelines.